IMCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient investor: the chart is in a confirmed downtrend (SMA200 > SMA20 > SMA5) with negative momentum (MACD histogram -0.16 and worsening).", "Near-term support is close (S1 31.854 / S2 30.766) and price (31.49) is already below the pivot (33.615), so downside risk to the next support band remains immediate.", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: No signal on given stock today.\n- SwingMax: No signal on given stock recently.", "Wall Street sentiment has improved meaningfully (UBS upgrade to Buy with a large target hike), but the current tape is still bearish; I would not chase a fresh entry today."]
["Trend: Bearish (SMA_200 > SMA_20 > SMA_5), consistent with a declining intermediate/long-term structure.", "Momentum: MACD histogram -0.16 and negatively expanding -> selling pressure is increasing rather than stabilizing.", "RSI(6): 23.94 -> deeply oversold on the short lookback, which can spark bounces, but oversold readings can persist in strong downtrends.", "Levels: Pivot 33.615 (overhead), Resistance R1 35.376 / R2 36.464; Support S1 31.854 (immediate) / S2 30.766 (next). With price at 31.49, the market is testing the support zone now.", "Pattern-based odds provided: 60% chance of +0.43% next day, +2.53% next week, +5.96% next month\u2014modest upside probabilities, but they conflict with currently weakening MACD/MA structure."]
["Analyst catalyst: UBS upgraded to Buy (from Sell) and raised PT to $55 (from $24), signaling a major sentiment inflection from at least one street firm.", "Operational continuity: Promotions of the CMO and Head of Regulatory Sciences to EVP roles may reduce execution risk after the R&D leadership change.", "Commercial foundation: KIMMTRAK already approved in 39 countries (per company), supporting the revenue base."]
can be interpreted as an execution/continuity risk even if management frames it positively.", "Options positioning mixed: High put open interest (OI PCR 2.
implies meaningful hedging/defensive positioning remains in place."]
["Latest quarter (2025/Q3): Revenue $103.693M, +29.22% YoY (strong top-line growth).", "Profitability: Net income -$0.177M (down 102.03% YoY) and EPS 0 (down 100% YoY) -> profitability deteriorated vs prior year (near breakeven but negative).", "Margins: Gross margin 99.51% (+0.07% YoY) remains extremely high, consistent with strong product economics; the key issue is operating expense scaling vs revenue."]
["Recent trend: Price targets have been moving up (Morgan Stanley to $40; Mizuho to $37; UBS to $55) indicating improving expectations.", "Ratings: UBS turned bullish (Buy). Morgan Stanley remains neutral-ish (Equal Weight). Mizuho remains Neutral.", "Wall Street pros: Improving biotech tape expectations into 2026, commercial-stage story, and higher targets suggest increasing confidence.", "Wall Street cons: Multiple neutrals remain, implying consensus is not fully convinced on near-term upside/execution; the current chart weakness also supports a more cautious stance."]
